

# **The Versatility of Q-TOF HRMS in Bioanalysis**

From Small Peptides Quantitation to Protein Complexes Characterization

Zhuo Chen, PhD GlaxoSmithKline




## The Sensitive and Robust Quantitation of Intact Peptide Hormones Using Q-TOF HRMS




## **Comparison of Two Mass Spectrometers on Protein Quantitation**

### QQQ (Waters Xevo TQ-XS)



### **Q-TOF (Waters Xevo G2-XS)**






## **Optimal MRM Methods are Similar in QQQ and Q-TOF**

| Hormone        | M.W. | Precursor Ion Product Ion |                                     | CE in<br>QQQ | CE in<br>Q-TOF |
|----------------|------|---------------------------|-------------------------------------|--------------|----------------|
| Angiotensin II | 1046 | 523.7760 (2+)             | 784.4098 (b6, 1+)                   | 19           | 19             |
| Endothelin-1   | 2492 | 831.3429 (3+)             | 1144.4747 (b20, 2+)                 | 20           | 20             |
| Endothelin-3   | 2643 | 661.5337 (4+)             | 1163.4775 (b19, 2+)                 | 18           | 17             |
| ANP            | 3080 | 616.8918 (5+)             | 584.2767 (b27+H <sub>2</sub> O, 5+) | 24           | 26             |
| IAPP           | 3903 | 976.7201 (4+)             | 883.7466 (b25, 3+)                  | 31           | 35             |
| CRF            | 4757 | 793.7496 (6+)             | 883.2783 (y38, 5+)                  | 21           | 22             |
| Insulin        | 5807 | 1162.5286 (5+)            | 345.2107 (y3 from chain B, 1+)      | 44           | 44             |
| PTH            | 9424 | 725.9220 (13+)            | 770.8134 (y82, 12+)                 | 19           | 19             |

• Optimal MRM methods are the same in buffer and matrix (plasma).



### - Sample preparation

- Spike hormone mixture (10 pg/mL 1000 ng/mL) into 50 µL of human plasma, two sets of calibration standards. Three levels of QCs in four replicates.
- After SPE cleanup (Waters HLB), dry and reconstitute elution. Inject 15 μL to LC/MS.


### – LC/MS method

- iKey microflow: 2.5 min of trapping time (15 μL/min) and 12 min of analytical time (3 μL/min, 8 min gradient 1-70% B + 4 min wash and re-equilibrate)
- For TOF-MRM data, integration over 0.05 Da mass extraction window.

## **Quantitation Performance for Seven Intact Hormones Using QQQ or TOF-MRM**




|       |                                   | ET-1   | ET-3   | ANP    | IAPP            | CRF           | INS    | PTH    |
|-------|-----------------------------------|--------|--------|--------|-----------------|---------------|--------|--------|
| QQQ   | r <sup>2</sup>                    | 0.9926 | 0.9937 | 0.9903 | 0.9880          | 0.9907        | 0.9887 | 0.9885 |
|       | LLOQ (ng/ml)                      | 0.01   | 0.01   | 0.05   | 0.1             | 0.5           | 0.1    | 2      |
|       | HLOQ (ng/ml)                      | ≥1000  | ≥1000  | ≥1000  | ≥1000           | ≥1000         | 500    | ≥1000  |
|       | Linear range (Log <sub>10</sub> ) | ≥5.0   | ≥5.0   | ≥4.3   | ≥4.0            | ≥3.3          | ≥3.7   | ≥2.7   |
| Q-TOF | r <sup>2</sup>                    | 0.9779 | 0.9759 | 0.9716 | 0.9810          | 0.9932        | 0.9877 | 0.9848 |
|       | LLOQ (ng/ml)                      | 0.02   | 0.05   | 0.5    | 0.5             | 1             | 0.05   | 20     |
|       | HLOQ (ng/ml)                      | 50     | 200    | 500    | <u>≥</u> 1000   | <u>≥</u> 1000 | 200    | ≥1000  |
|       | Linear range (Log <sub>10</sub> ) | 3.4    | 3.6    | 3.0    | <u>&gt;</u> 3.3 | <u>≥</u> 3.0  | 3.6    | ≥1.7   |



Indirect Quantitation (proteolytic peptides)




### **Higher Selectivity of Q-TOF Decreases Endogenous Interferences**



Parathyroid hormone (1): SLGEADKADVNVLTK (MH3<sup>+</sup>  $\rightarrow$  y13<sup>++</sup>)

# Some Interference Issues Cannot be Solved by Higher Selectivity of HRMS Chromatogram Optimization is Still Necessary in Some Cases



Corticotropin-releasing hormone: EVLEMAR (MH2<sup>+</sup>  $\rightarrow$  y4)

## Conclusion



- Quantitation Performance of Q-TOF HRMS compared to QQQ
  - Both instruments can accurately quantitate peptides up to ~ 10 kDa in a multiplexed manner with *at least 3-4 orders of magnitude* of linear dynamic range
  - Compared to Q-TOF, QQQ provides *slightly* better sensitivity and wider dynamic range.
  - Higher selectivity of *Q-TOF may decrease endogenous interferences* leading to reduced chromatograph run time and higher confidence of assay development.
- Data Processing
  - TOF-MRM function reduces file size to the appropriate level for continuous bioanalytical use: ~40 MB with TOF-MRM and ~0.8 MB with QQQ.
  - Processing time is **NOT** significantly increased with TOF-MRM data with TargetLynx.



# Native HRMS Analysis of Noncovalent Protein Complexes up to 450 kDa



 Buffers for conventional intact protein analysis usually contain strong acids to denature proteins and destroy noncovalent protein–protein interactions.

Benefits of Native MS

- In native MS, proteins or noncovalent complexes are retained in their native state in the gas phase, and thus the integrity of proteins is not disrupted.
- Direct analysis of noncovalent protein interactions has great potential to elucidate the pharmacology/toxicology of mAbs and target engagement.

Technical Limitation - Instrumentation modifications are usually required to transmit large ions in the native state with high m/z.



• **Sample:** GSK mAb (145.9 kDa), buffer exchanged (3x with Vivaspin 30 kDa MWCO) into 50 mM ammonium acetate pH 6.8 (final concentration of 2 mg/mL)

• Instrument and injection mode: Waters Synapt G2-S in ESI+/Sensitivity/MS mode with Z-Spray ion source, direct infusion with Hamilton syringe pump at 10 µL/min

- Exploration of instrumental settings
- Infusion flow rate: 5, 10, 15, 20 µL/min
- > Capillary Voltage: 2.5, 3.0, 3.5 kV
- > Sample Cone: 50, 100, 150 V
- Source Offset: 50, 105
- > Source Temperature: 60,100,120 °C


> Desolvation Temperature: 200, 300, 600 °C


Showed limited impact on peak intensity or system robustness, but no observable influence on native MS



### Mass Spectrum of GSK mAb at Different Desolvation Temperatures

MS conditions: Infusion flow rate 10 µL/min, capillary voltage 2.6 kV, source temperature 80 °C, sample cone voltage 30 V, source offset 30, desolvation gas flow 200 L/hr.








• Samples: GSK mAb (145.9 kDa) and its target protein antigen (82.7 kDa)

• Prepare 10  $\mu$ M GSK mAb solution and 10  $\mu$ M antigen solution in PBS; incubate two solutions with three different mole ratios at 3:1, 1:1, 1:3 at 37 °C for 2 hr.

• After incubation, the solution was buffer exchanged (3x with Vivaspin 30 kDa MWCO) into 50 mM ammonium acetate pH 6.8. Final protein concentration is ~ 0.5 mg/ml.



### **Native MS Analysis of Antigen-Antibody Complex**




• Native MS can provide an accurate qualitative analysis of protein complex consistent with subunit stoichiometry.

• Non-covalent complexes could not be observed under denaturing conditions.

• Native MS parameters optimized by non-covalent complexes or single protein were consistent.



### **Native MS Analysis of Antibody-ADA Complex**



- Protein complexes (up to ~450 kDa) with similar components but slightly different masses can be distinguished.
- Detection of CsI signals proved that *m*/z 9000 is the practical upper limit of this commercial Q-TOF without modification.

### Conclusion



- It is feasible to use a commercially available Q-TOF HRMS and ESI ion source without any modification to perform native MS analysis.
- Desolvation temperature is a very important parameter for native MS.
- In vitro noncovalent binding of GSK mAb with its target and ADAs was characterized, and the results were consistent with the subunit stoichiometry of these protein assemblies.
- A molecular weight around 450 kDa for native MS analysis, is the upper detection limit of this commercial instrument under the default configuration.
- Future direction may focus on *in vivo* studies that process samples in biological matrices without compromising the compatibility with native MS.

#### 19

## **Acknowledgements**

- GSK Protein Mass Spectrometry Group \_ John Mehl Timothy Sikorski John Kellie Thomas Angel Waters Bo An Mark Wrona Ahmed Moghieb Yun Alelyunas Nicole Schneck Ian Edwards Lela Mortezavi Kelly Doering
- GSK Bioanalysis, Immunogenicity, and Biomarker (BIB)
  Eric Yang
  Huaping Tang



